Allergan depression treatment fails studies, shares slip

Allergan Plc said on Wednesday its experimental add-on treatment for depression failed three late-stage studies, casting doubts over its drugs pipeline and sending the Botox-maker's shares down nearly 4 percent after the bell.

from Reuters: Health https://ift.tt/2HjKyMk
via IFTTT

• Tweet
• Share
• Share
• Share
• Share